These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 18614401)

  • 21. [Techniques of preparation and indications of labile blood products].
    Clément S
    Transfus Clin Biol; 2011 Apr; 18(2):250-61. PubMed ID: 21474355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Labile blood products and their preparation].
    Chabanel A; Folléa G
    Rev Prat; 2001 Jun; 51(12):1306-10. PubMed ID: 11503503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Ensuring the safety of donated blood].
    Danic B
    Rev Infirm; 2012 Jan; (177):18-20. PubMed ID: 22372105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In search of plentiful universal donor plasma: what might Landsteiner say?
    Quillen K
    Transfusion; 2013 Aug; 53(8):1863-4. PubMed ID: 23927641
    [No Abstract]   [Full Text] [Related]  

  • 25. Bacterial contamination of cellular blood components: risks, sources and control.
    Blajchman MA
    Vox Sang; 2004 Jul; 87 Suppl1():98-103. PubMed ID: 15200616
    [No Abstract]   [Full Text] [Related]  

  • 26. Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma?
    Hellstern P
    Transfus Apher Sci; 2008 Aug; 39(1):69-74. PubMed ID: 18583192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogen reduction technologies: what are the concerns?
    AuBuchon JP
    Vox Sang; 2004 Jul; 87 Suppl 2():84-9. PubMed ID: 15209887
    [No Abstract]   [Full Text] [Related]  

  • 28. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies.
    Picker SM; Schneider V; Gathof BS
    Transfusion; 2009 Jun; 49(6):1224-32. PubMed ID: 19220821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Skin disinfection and bacterial contamination of blood components: be simple.
    Bueno JL
    Transfusion; 2010 Jan; 50(1):5-8. PubMed ID: 20233345
    [No Abstract]   [Full Text] [Related]  

  • 30. Highlights of PBTI Coimbra Conference on PRT of Plasma & Current Opinions on Pathogen Reduction Treatment of Blood Components.
    de Sousa G; Seghatchian J
    Transfus Apher Sci; 2015 Apr; 52(2):228-32. PubMed ID: 25770045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful removal of Chlamydia pneumoniae from plateletpheresis products collected using automated leukoreduction hemapheresis techniques.
    Webley W; Stuart E; Cirino F; Cahill F; Stec T; Andrzejewski C
    J Clin Apher; 2006 Oct; 21(3):195-201. PubMed ID: 16570261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation.
    Fast LD; DiLeone G; Marschner S
    Transfusion; 2011 Jul; 51(7):1397-404. PubMed ID: 21155832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Balancing evidence and public opinion in health technology assessments: the case of leukoreduction.
    Cleemput I; Leys M; Ramaekers D; Bonneux L
    Int J Technol Assess Health Care; 2006; 22(4):403-7. PubMed ID: 16984672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current trends in blood component therapy: the evolution of a safer, more effective product.
    Baranowski L
    J Intraven Nurs; 1992; 15(3):136-51. PubMed ID: 1608013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogen inactivation: emerging indications.
    Kleinman S
    Curr Opin Hematol; 2015 Nov; 22(6):547-53. PubMed ID: 26390164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacterial risk reduction by improved donor arm disinfection, diversion and bacterial screening.
    McDonald CP
    Transfus Med; 2006 Dec; 16(6):381-96. PubMed ID: 17163869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron and blood donation- an under-recognised safety issue.
    Farrugia A
    Dev Biol (Basel); 2007; 127():137-46. PubMed ID: 17486886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood banking and transfusion medicine for the nephrologist.
    Wehrli G
    Semin Dial; 2012; 25(2):114-8. PubMed ID: 22276991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experience with routine total nonfasting blood cholesterol screening of volunteer blood and component donors.
    Eason S; Goudar S; Centilli J; Sayers M
    Transfusion; 2011 Apr; 51(4):731-6. PubMed ID: 20977488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Innovative technology and blood safety].
    Begue S; Morel P; Djoudi R
    Transfus Clin Biol; 2016 Nov; 23(4):245-252. PubMed ID: 27616610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.